- Home
- Protocols and Guidelines
- Current CAP Guidelines
- Human Papillomavirus Testing in Head and Neck Carcinomas
Background
Our evidence-based, clinical practice guideline “Human Papillomavirus (HPV) Testing in Head and Neck Carcinomas” helps to standardize testing for HPV in head and neck carcinomas. It recommends that all patients with newly diagnosed oropharyngeal squamous cell carcinoma be tested for high-risk HPV.
The guideline was developed by our Pathology and Laboratory Quality Center of Evidence-based Guidelines and its interdisciplinary, expert panel of surgical and molecular pathologists, cytopathologists, head and neck surgeons, and radiation and medical oncologists. The panel screened more than 2,200 articles and reviewed evidence from 492 studies to develop a total of 14 guideline recommendations.
Clinical teams should adopt the guideline, available in the Archives of Pathology & Laboratory Medicine, to ensure eligible patients receive consistent, accurate assessment of HPV status.
Guideline Information
- Status: Active
- Published online ahead of print: December 18, 2017
- Originally published: May 2018
Guideline Tools and Resources
Download the following tools and resources to help implement the guideline:
- Summary of Recommendations (PDF, 107 KB)
- Methodology Supplement (Supplemental Digital Content) (PDF, 623 KB)
- Teaching Presentation (PDF, 3.6 MB)
- HPV Testing in Head and Neck Algorithm (PDF, 133 KB)
- Frequently Asked Questions (PDF, 171 KB)
- Infographic (PDF, 595 KB)